Niemann Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Niemann Capital Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,493	Closed	-$285K	–	12
2015 Q3	$285K	Sell	2,493 -3,823	-61%	-$506K	0.43%	14
2015 Q2	$852K	Sell	6,316 -350	-5%	-$46.5K	0.61%	18
2015 Q1	$864K	Sell	6,666 -419	-6%	-$52.7K	0.58%	19
2014 Q4	$817K	Buy	+7,085	New	+$798K	0.58%	20
2014 Q2	–	Sell	-157,929	Closed	-$14.4M	–	22
2014 Q1	$14.4M	Buy	157,929 +40	+0%	+$3.89K	9.78%	3
2013 Q4	$14M	Sell	157,889 -13,060	-8%	-$1.09M	9.63%	3
2013 Q3	$14.1M	Sell	170,949 -15,106	-8%	-$1.19M	10.18%	3
2013 Q2	$12.7M	Buy	+186,055	New	+$12.9M	10.5%	3

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

VFAM

Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Niemann Capital Management's BBH Position: Q4 2015 in Review

Niemann Capital Management sold out of VanEck Biotech ETF (BBH) in Q4 2015, closing a stake of 2,493 shares — an estimated $285K sold.

Niemann Capital Management first reported a position in BBH in Q2 2013 and held it in 8 quarters. The position peaked at $14.4M in Q1 2014. 90 funds tracked by Wall St. Rank hold BBH as of Q4 2015.

Niemann Capital Management reported no remaining VanEck Biotech ETF position as of Q4 2015 after selling out during the quarter.
Niemann Capital Management sold 2,493 VanEck Biotech ETF shares in Q4 2015, an estimated $285K.
Niemann Capital Management first reported a position in VanEck Biotech ETF in Q2 2013 and held it in 8 quarters.
Niemann Capital Management's VanEck Biotech ETF position peaked at $14.4M in Q1 2014.
90 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2015.

Based on Niemann Capital Management's 13F filing for Q4 2015, filed 29 Jan 2016.